leadf
logo-loader
viewIQ-AI Limited

IQ-AI Limited subsidiary Imaging Biometrics teams up with Mayo Clinic to develop brain lesion tracking platform

"We are excited to team up with the Mayo Clinic to significantly expand the diagnostic utility of our core applications,” said Michael Schmainda, chief executive of IB

IQ-AI Limited -

IQ-AI Limited (LON:IQAI) subsidiary Imaging Biometrics (IB) said it has teamed up with the world-renowned Mayo Clinic to develop a brain lesion tracking platform to be called IB Trax.

Using artificial intelligence, the new technology will be used to assess the development of metastatic and primary brain tumours.

IB's quantitative expertise will form the foundation of IB Trax with clinical input provided by the May Clinic, IQ-AI said.

"We are excited to team up with the Mayo Clinic to significantly expand the diagnostic utility of our core applications,” said Michael Schmainda, chief executive of IB in a statement.

“This collaboration provides key clinical input to further enhance the design and guide development of IB Trax."

The US medical group will receive what is described as a ‘token’ US$50,000 of shares in IQ-AI, and will be handed US$10,000 more in stock each year the agreement exists. It has also been given a 4% royalty on each sale of IB Trax, including US$20,000 on the initial commercial installation.

The deal builds on an already strong relationship with the Mayo that has seen appointment to IB’s scientific advisory board of Dr Leland Hu, assistant professor of radiology at the clinic’s Arizona campus.

Quick facts: IQ-AI Limited

Price: 8.5 GBX

LSE:IQAI
Market: LSE
Market Cap: £14.46 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

IQ-AI's Imaging Biometrics developing technology that could 'revolutionise...

Michael Schmainda, co-founder and CEO of IQ-AI Limited's (LON:IQAI) subsidiary Imaging Biometrics tells Proactive London's Andrew Scott they're developing a technology that could revolutionise the detection and treatment of brain tumours. IB CAD has been created to pick up cancer cells before...

on 15/7/20

2 min read